A South Korean company will supply the US military with quick COVID-19 test kits.
Celltrion, a South Korean biopharmaceutical company, has agreed to supply the US military with their DiaTrust fast COVID-19 test kit.
Celltrion USA said on Thursday that the Defense Logistics Agency of the United States Department of Defense has granted the business a $626 million procurement contract.
Celltrion will supply its goods to around 25,000 selected places under the deal, including military posts, long-term care facilities, and community testing sites.
DiaTrust, which can detect an infection in about 15 minutes, received emergency use authorisation from the US Food and Drug Administration earlier this year.
DiaTrust has a sensitivity of 93.3 percent and a specificity of 99 percent, according to Celltrion. The former represents how frequently a test provides a positive result correctly, whereas the latter indicates how frequently a test generates a negative result correctly.
Unlike other over-the-counter items, the diagnostic kits can only be used in the presence of medical professionals, according to the business.
With the COVID-19 pandemic showing no signs of abating, Celltrion USA CEO Kim Bon-joong said in a statement, “We plan to focus on executing this contact as meticulously as possible and further cement the external trust of Celltrion’s diagnostic test kits.”
Meanwhile, Celltrion reported this week that the Ministry of Food and Medication Safety in South Korea has approved Regkirona, a COVID-19 antibody drug.
In February, the Regkirona medication received conditional approval and has only been used in South Korea to treat high-risk individuals. However, patients with mild or moderate symptoms will be able to use the medicine now that it has received legal approval.
Celltrion said it will also strive to get the treatment approved in other nations.
Inhalon Biopharma, a firm based in the United States, is developing an oral medicine with the corporation, and its Phase 1 study has been approved in Australia.
Companies including MSD, Roche, and Pfizer are leading the charge in developing COVID-19 oral antiviral medicines, with Phase 3 trials underway.
At nokiamobilephonenews.co.uk, Nokia News provides an independent, constantly updated stream of breaking news from the United States and throughout the world.